After recovering sharply from its 52-week low of $47.32, Haemonetics Corporation (HAE) has rallied back toward the $80 mark, prompting investors to ask whether the medical technology company can push through to $90. That target is not arbitrary — it sits just above the stock's 52-week high of $87.32, meaning a move to $90 would represent a decisive breakout into territory not seen in over a year. Several Wall Street analysts have published price targets at or near this level, including Mizuho Securities, which recently raised its target to $90, and Barrington Research, which maintains an $89 target. The round-number psychology of $90 also makes it a natural focal point for traders and institutional investors assessing the risk-reward profile of the stock.
Haemonetics Corporation, headquartered in Boston, Massachusetts, is a global healthcare company that designs, manufactures, and markets blood processing systems and hospital technologies. The company operates through three primary segments: Plasma, Blood Center, and Hospital. Its product portfolio includes automated plasma collection systems such as NexSys PCS and PCS2, donor management software, hemostasis management products, and vascular closure devices including the VASCADE family. Haemonetics recently underwent a business realignment, merging Plasma and Blood Center into a single Apheresis segment and renaming Hospital as MedSurg, reflecting how management now runs the organization. With a market capitalization of approximately $3.64 billion and roughly 3,600 employees, Haemonetics serves customers across the United States and internationally.
As of the market close on July 27, 2026, Haemonetics shares traded at approximately $80.11, reflecting a gain of more than 65% from the 52-week trough. The stock has staged an impressive recovery since bottoming near $47 in early 2026, fueled by stabilizing plasma end-market demand, better-than-expected earnings results, and renewed analyst confidence. Despite the recent momentum, the stock remains approximately 8% below its 52-week high, and the trailing twelve-month financial picture shows mixed results: revenue declined roughly 2% year-over-year to $1.33 billion, while net income contracted by approximately 42% to $97.31 million. However, forward-looking estimates are more encouraging, with the forward P/E (price-to-earnings) ratio sitting at roughly 15.4, suggesting earnings recovery is priced into expectations.
Several catalysts could propel Haemonetics toward the $90 level. First, the plasma segment — long the company's largest revenue driver — is showing signs of stabilization after navigating the CSL contract wind-down. Haemonetics holds an estimated 80% market share in plasma collection software and continues upgrading customers to its NexSys with Persona platform, which commands premium pricing and higher margins. Second, the Hospital segment, which includes hemostasis management and vascular closure devices, posted double-digit organic growth in recent quarters. The launch of VASCADE MVP XL, featuring a 58% larger plug size for large-bore procedures including pulsed field ablation and left atrial appendage closure, expands the addressable market. Third, Haemonetics has been actively repurchasing shares, completing a $75 million buyback covering nearly 3% of outstanding shares, which supports earnings per share (EPS) on a per-share basis even if absolute earnings face headwinds. Finally, Haemonetics has reiterated its long-range plan to reach a "high-20%" operating margin, and incremental margin expansion would strengthen the bull case considerably.
Wall Street coverage of Haemonetics reflects a generally constructive but measured outlook. Of the 11 analysts tracked by S&P Global, the consensus rating stands at "Buy," with an average 12-month price target of approximately $86.60. The highest target on the Street reaches $104, while the lowest sits at $62. Notable recent actions include Mizuho raising its target to $90 with an Outperform rating, BTIG maintaining a Buy rating with an $84 target, and Bank of America Securities upgrading the stock to Buy with an $80 target. On the more cautious side, J.P. Morgan maintains a Neutral rating with a $62 target, and Citi holds at Neutral with a $79 target while adding a "downside 90-day catalyst watch." The dispersion among analyst targets — spanning $62 to $104 — underscores the genuine uncertainty surrounding the pace of Haemonetics' post-CSL transition and the sustainability of its Hospital segment growth trajectory.
The path to $90 is not without obstacles. The CSL contract, which previously represented a material portion of plasma revenue, is in its final unwind phase, and Haemonetics has guided to minimal CSL contributions going forward. This creates a revenue hole that the remainder of the business must fill through organic growth. In addition, the company's vascular closure portfolio faces competitive pressures — management has acknowledged losing share in the small-bore VASCADE product, which accounts for roughly 15% of the closure business. Broader macroeconomic concerns, including hospital capital spending restraint and potential reimbursement changes, could also weigh on near-term growth. The company's trailing P/E of roughly 39 reflects depressed current earnings; if the earnings recovery stalls, the stock could struggle to command a premium multiple. Furthermore, institutional ownership has declined in recent quarters, with total shares held by institutions dropping by approximately 6-7% in some reporting periods, signaling some professional investors are reducing exposure.
From a technical standpoint, the $87.32 level represents the immediate hurdle — the 52-week high established during the stock's prior uptrend. A close above this level on above-average volume would signal a bullish breakout and open the door to $90. On the downside, support appears to have formed in the $70-$74 zone, an area that previously acted as resistance during the recovery rally and has since been tested successfully as support. A breach below that zone would call the recovery narrative into question. The stock's beta of 0.52 indicates relatively low volatility compared to the broader market, suggesting that any move toward $90 would likely be methodical rather than explosive.
For traders seeking a data-driven edge in navigating Haemonetics' price action, Tickeron's AI Daily Buy/Sell Signals offer a powerful resource. This platform leverages artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical patterns, and AI-driven analysis. Rather than manually scanning charts and news feeds, traders can use these signals to efficiently discover emerging opportunities, track existing positions, and identify shifts in market trends before they become obvious. Whether the question is whether HAE can sustain its rally toward $90 or whether momentum is fading, AI-driven signals can help cut through the noise and provide timely, actionable insight.
The question of whether Haemonetics can reach $90 appears realistic but conditional. The stock currently trades at roughly $80, meaning a move to $90 requires approximately 12.5% upside — far from a stretch given the recovery already logged from the mid-$40s. The strongest arguments in favor include the stabilizing plasma business, continued momentum in Hospital and hemostasis products, a supportive analyst consensus, and an active share repurchase program. On the other hand, the CSL revenue headwind, competitive share losses in portions of the vascular closure portfolio, and mixed institutional sentiment present genuine hurdles. For $90 to materialize, investors would likely need to see a clean quarterly report with revenue re-acceleration, margin expansion consistent with the long-range plan, and evidence that new products such as VASCADE MVP XL are gaining commercial traction. Monitoring the August 2026 earnings release, plasma collection volume data, and operating margin progression will be essential for gauging whether the $90 target moves from plausible to probable.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, HAE has been loosely correlated with SRTS. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if HAE jumps, then SRTS could also see price increases.
| Ticker / NAME | Correlation To HAE | 1D Price Change % | ||
|---|---|---|---|---|
| HAE | 100% | +0.85% | ||
| SRTS - HAE | 44% Loosely correlated | +0.69% | ||
| ECOR - HAE | 43% Loosely correlated | -3.26% | ||
| ATR - HAE | 41% Loosely correlated | +0.07% | ||
| GH - HAE | 39% Loosely correlated | +6.33% | ||
| PFSA - HAE | 38% Loosely correlated | N/A | ||
More | ||||
| Ticker / NAME | Correlation To HAE | 1D Price Change % |
|---|---|---|
| HAE | 100% | +0.85% |
| Health Services category (245 stocks) | -1% Poorly correlated | -0.79% |
| Medical/Nursing Services category (140 stocks) | -1% Poorly correlated | -1.20% |